Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individuals
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual|
- Compliance with study requirements which include both medication,attendance at treatment sessions and topiramate level. [ Time Frame: Throughout the study ]
- adverse events, PE, lab results, withdrawal from alcohol,GGT, CDT,self-report measures of alcohol consumption - DDD and PDA,self-report measures of binge eating behavior-Binge eating episodes and Binge eating days.Quality of life, mood state, craving. [ Time Frame: Throughout the study ]
|Study Start Date:||March 2006|
|Study Completion Date:||July 2008|
|Primary Completion Date:||July 2008 (Final data collection date for primary outcome measure)|
Topiramate up to 300 mg per day.
Other Name: Topamax
Research has shown an alarming coincidence of binge eaters also reporting serious alcohol abuse. Evidence has shown this population to have higher rates of psychiatric comorbidity, higher caloric intakes during meals, higher rates of tobacco use, more frequent binge episodes, and an earlier age of onset for binge eating and alcohol abuse. It is believed that topiramate may reduce binge eating and has been found helpful in reducing the cravings associated with alcohol consumption.
This study is to test the feasibility of administering topiramate to individuals with alcohol dependence and binge eating disorder. This will involve determining the adequacy of the amount of assessment and scheduled visits.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00300742
|United States, Virginia|
|Charlottesville, Virginia, United States, 22911|
|UVA CARE Richmond|
|Richmond, Virginia, United States, 23294|
|Principal Investigator:||Nassima Ait-Daoud, MD||University of Virginia, Department of Psychiatric Medicine|